{"filing":{"accession_number":"0001628280-26-057804","cik":"0001516551","ticker":"SKYE","company_name":"Skye Bioscience, Inc.","form":"8-K","filing_date":"2026-08-18","report_date":"2026-08-18","primary_document":"skye-20260818.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm"},"events":[{"id":28352,"run_id":25924,"accession_number":"0001628280-26-057804","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Skye Bioscience received a written notice from Nasdaq on August 18, 2026, stating that the company failed to comply with Nasdaq Capital Market Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. The company's stockholders' equity was ($497,307)—negative—as of June 30, 2026. Although the notice has no immediate effect on listing, the company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that \"there can be no assurance that the Company will be able to regain compliance.\" This is a classic delisting-risk disclosure under Item 3.01.","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-08-18","form":"8-K","submitted_at":null,"items":[{"id":30270,"accession_number":"0001628280-26-057804","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Skye Bioscience received a written notice from Nasdaq on August 18, 2026, stating that the company failed to comply with Nasdaq Capital Market Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. The company's stockholders' equity was ($497,307)—negative—as of June 30, 2026. Although the notice has no immediate effect on listing, the company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that \"there can be no assurance that the Company will be able to regain compliance.\" This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T10:03:55.609118+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30270,"accession_number":"0001628280-26-057804","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Skye Bioscience received a written notice from Nasdaq on August 18, 2026, stating that the company failed to comply with Nasdaq Capital Market Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. The company's stockholders' equity was ($497,307)—negative—as of June 30, 2026. Although the notice has no immediate effect on listing, the company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that \"there can be no assurance that the Company will be able to regain compliance.\" This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T10:03:55.609118+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-08-18"}]}